Pfizer to phase out Sydney manufacturing by the end of 2015.
Prizer has just announced the closure of its manufacturing operations in Sydney, with about 140 jobs affected.
The factory produces solid oral dose products – tablets and capsules – in the human and animal health area.
“This has been a difficult decision, and reflects the need to align our global manufacturing capacity with the needs of our business,” said Manufacturing Operations Director, Justin Mathie.
“Pfizer has been reviewing our global manufacturing network and capacity in response to changing global demand as a result of the patent expiry of a number of key medicines,” Mathie added.
“In addition our industry is seeing a trend away from high-volume medicines, to high value but lower volume medicines that target a specific patient population or disease condition,” he said, with this necessitating more flexible manufacturing facilities and a different overall approach.
Pfizer’s Perth facility will continue to manufacture sterile injectables for the domestic and export markets.
The closure has no impact on Pfizer’s commercial operations or the supply of its medicines in Australia.
More information in tomorrow’s Pharmacy Daily.
